Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. (en)
|
foaf:name
| - Juno Therapeutics Inc (en)
|
foaf:homepage
| |
name
| - Juno Therapeutics Inc (en)
|
foaf:depiction
| |
location
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
foundation
| |
homepage
| |
industry
| |
key people
| - Hans Bishop (en)
- Hyam Levitsky, M.D. (en)
- Mark Gilbert, M.D. (en)
- Steve Harr, M.D. (en)
|
location
| |
logo
| - File:Juno Therapeutics logo.jpg (en)
|
parent
| |
type
| |
has abstract
| - Juno Therapeutics Inc is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene. (en)
|
gold:hypernym
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
founding year
| |
industry
| |
key person
| |
parent company
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |